drugset / Trial / NCT01636076

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01636076

Phase 2 Completed 629 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD

Timeline

Start
2012-11
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 500 ug
Subject Indacaterol Other / unclassified 150 ug
Subject Mometasone Other / unclassified 160 ug
Comparator Salmeterol Other / unclassified 50 ug